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Abstract
Background: This study compared carotid ultrasound (CUS) and traditional risk calculations in determining
cardiovascular disease (CVD) risk in patients with type 2 diabetes mellitus (DM) and investigated whether
awareness of CVD affects patient and/or physician behavior.
Methods: In this prospective, observational, multicenter study, 797 participants with type 2 diabetes were
assessed using CUS, the United Kingdom Prospective Diabetes Study Risk Engine (UKPDSRE) calculator, and
the Framingham Risk Score (FRS) algorithm. Health-related behaviors and physician treatments were compared
at baseline and at 6 months after assessment.
Results: According to CUS, 43.5 % of the participants were at high risk (compared to 10.6 % and 4.3 % using the
UKPDSRE and FRS approaches, respectively). Interestingly, 31.5 % of the patients with low risk scores according to the
UKPDSRE calculator and 35.8 % of the patients with low risk scores according to the FRS algorithm were found to be at
high risk according to CUS. The proportion of patients who achieved target LDL-C levels significantly increased after
CUS. Moreover, increased awareness of atherosclerosis through CUS findings significantly altered physician treatment
patterns and patient health-related behaviors.
Conclusions: Carotid atherosclerosis was detected in more than 30 % of all participants with low or intermediate risk
stratification scores. Improved awareness of atherosclerosis through CUS findings had a positive impact on both
patient and physician behavior, resulting in improved CV risk management.
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Background
Cardiovascular disease (CVD) is a major cause of
mortality and morbidity in patients with type 2 diabetes
mellitus (DM), making early diagnosis and treatment of
atherosclerosis extremely important [1]. However, most
patients with diabetes with subclinical atherosclerosis
are asymptomatic [2]. In addition, the prevalence of
silent myocardial ischemia (MI) is much higher in pa-
tients with diabetes compared to the general population
[3]. Thus, in order to provide optimal medical therapy to
prevent future cardiac events, identification of patients
who are at high risk for CVD is of prime importance.
The current guidelines on CVD prevention recommend
targeted management of CV risk factors after assessment
using one of the many available methods, even in
asymptomatic patients.
Cardiovascular disease risk analysis can be performed
using well-known risk-stratification approaches, including
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the Framingham Risk Score (FRS) algorithm [4] and the
United Kingdom Prospective Diabetes Study Risk Engine
(UKPDSRE) calculator [5]. The results of the FRS and
UKPDSRE approaches, which include traditional CV risk
factors, generally correlate with coronary heart disease risk
[4]. However, a substantial number of people with low
(<10 %) to intermediate (10–20 %) FRS scores go on to
develop atherosclerosis [6]. Previous reports have also
demonstrated that the UKPDSRE lacks adequate sensitiv-
ity and specificity for detection of subclinical atheroscler-
osis [7]. Therefore, additional tools are needed to improve
CV risk assessment.
Recent investigations have shown that noninvasive
techniques, such as carotid intima media thickness
(CIMT), presence of plaque, coronary artery calcium
score (CACS), ankle-brachial index (ABI), and aortic
pulse wave velocity may accurately detect subclinical
atherosclerosis that is associated with the development
of cardiovascular or cerebrovascular diseases [8]. These
studies have shown that imaging modalities are the best
method for detecting the presence and extent of ath-
erosclerosis. As such, it is important to conduct im-
aging studies in all patients regardless of the presence
of traditional CV risk factors, such as hypertension,
dyslipidemia, and diabetes mellitus, in order to com-
prehensively identify patients who are at risk for
developing CVD. We chose to focus our study on
CIMT because CUS is feasible in all individuals, dose
not involve exposure to radiation, and is relatively in-
expensive. When using imaging studies, a CACS >0,
stenosis >50th percentile, or the presence of plaque
are considered to be positive findings. These findings
suggest a high risk of developing CVD according to
the guidelines from the Screening for Heart Attack
Prevention and Education (SHAPE), published by the
Association for Eradication of Heart Attack (AEHA)
[9].
However, the outcomes of this guideline have not yet
been compared to those of the traditional guideline.
Therefore, we analyzed the prevalences of abnormal
carotid ultrasound (CUS) findings and compared them
to traditional risk stratification results obtained using
the FRS and UKPDSRE approaches.
Although physicians provide comprehensive treat-
ment for diabetes, hypertension, and dyslipidemia, pa-
tient drug compliance is critical for optimal outcomes.
If a physician assesses CVD risk and uses these results
to educate the patient about ways to prevent CVD, the
patient may implement lifestyle modifications or im-
prove his/her drug compliance. However, no studies
have yet investigated the effect of assessing subclinical
atherosclerosis on patient behavior, or whether aware-
ness of subclinical atherosclerosis alters physician treat-
ment patterns.
Here we explored how two distinct assessment
methods varied in their estimation of CV risk, a non-
invasive imaging test (CUS) and traditional risk calcu-
lators (UKPDSRE, FRS). We also examined how aware-
ness of being at high risk for CVD affected physician
treatment patterns as well as patient behavior with re-
spect to risk management. Our hypothesis was that re-
ceiving an explanation of CUS results, along with
proper education about mitigating risk factors, would
have a favorable effect on patient behavior and phys-
ician treatment plans.
Methods
This prospective, observational, multicenter study in-
cluded 797 patients with type 2 DM aged >40 years
who had never undergone a carotid ultrasound exam-
ination. Participants were recruited from 24 hospitals
in Korea. We excluded patients who had previously
undergone carotid artery ultrasound, or who had a
history of coronary artery disease, symptomatic con-
gestive heart failure, coronary revascularization, cere-
brovascular disease, stroke, transient ischemic attack,
or documented peripheral vascular disease (e.g. per-
ipheral artery disease, abdominal aneurysm, or carotid
artery stenosis). The investigation protocol was ap-
proved by the institutional review boards of each in-
stitution involved in the study. After obtaining
informed written consent, the height, weight, and
body mass index (BMI) (weight/height2, kg/m2) of
each patient were measured. Blood pressure was mea-
sured using a standard mercury sphygmomanometer.
All patients were interviewed prior to CUS examin-
ation. Questionnaires were administered using one-
on-one interviews and self-reporting techniques to
collect data on smoking; alcohol use; stress; dietary
habits; physical activity; past history of hypertension,
dyslipidemia, and atrial fibrillation; medication com-
pliance; and family history of CVD. The validated
Korean version [10] of Morsky’s self-reported ques-
tionnaire [11] was used to assess medication compli-
ance. Levels of fasting plasma glucose, HbA1C, total
cholesterol (TC), triglyceride (TG), high-density lipo-
protein cholesterol (HDL-C), and low-density lipopro-
tein cholesterol (LDL-C); current medications; and
the microalbumin-to-creatinine ratio within the past
1 month were collected by reviewing patient medical
records.
All subjects were assessed by CUS. Carotid intimal-
media thickness (IMT) was measured with the patient in
the supine position. A high-resolution B-mode ultra-
sound machine with a 7.5-MHz transducer was used on
the bilateral segments of the carotid arteries. The carotid
IMT was measured on the posterior far wall of the left
carotid artery. At least 4 measurements were taken, each
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about 1 cm proximal to the bifurcation. Positive criteria
for carotid atherosclerosis were defined as ≥1 mm of in-
tima medial thickness or the presence of plaque.
Although CUS was performed separately in the 24
different hospitals, each used a standardized protocol
recommended by the Mannheim carotid IMT consensus
report [12]. In addition, to adjust for potential intercen-
ter variations due to different sonographers, every
hospital used Intimascope software (Media Cross Co,
Ltd, Tokyo, Japan) for measurement. This software
performs automated IMT measurements based on an
algorithm that delineates the lumen-intima and media
adventitial interfaces [13].
Patients were stratified by risk using the UKPDSRE
and FRS assessments. A total of 622 patients provided
all required information to be assessed by the UKPDSRE
calculator and 648 patients provided sufficient informa-
tion to be assessed by the FRS algorithm. A total of 622
patients were assessed by CUS, UKPDSRE, and FRS.
The UKPDS calculator classified subjects into low
(<15 %), intermediate (15–30 %), or high (>30 %) 10-
year risk levels for CVD based on age, sex, duration of
diabetes, smoking, systolic blood pressure, total choles-
terol, HDL, ethnicity, and HbA1C [4]. The FRS algorithm
categorized subjects into low (<10 %), intermediate (10–
19 %), or high (≤20 %) 10-year risk levels for symptom-
atic CVD according to age, sex, lipid levels, blood pres-
sure, smoking, and presence of diabetes [5].
Blood samples were collected six months after carotid
IMT assessment to measure levels of TC, HDL-C, TG,
and LDL-C. Patients were also re-examined for changes
in responses to interview questions, physician prescrip-
tions, and patient behaviors.
All statistical analyses were completed using SAS (ver-
sion 9.2, USA). All data are presented as means ± stand-
ard deviations (SDs) or as numbers (percentages). To
compare clinical characteristics between the two groups,
an independent t-test was used for continuous variables
and a chi-squared test was used for categorical variables.
Multiple logistic regression analysis was used to analyze
the association between carotid IMT and CVD risk
factors. A paired t-test was used to measure changes in
patient behavior before and after they were informed
about their subclinical carotid atherosclerosis risk.
Differences with a p-level <0.05 were considered statisti-
cally significant.
Results
Baseline characteristics of the subjects with type 2 DM
Table 1 summarizes the clinical and laboratory measure-
ments of the subjects with type 2 DM included in this
study. The mean patient age was 60 years and the mean
BMI was 25.1 ± 3.1 kg/m2. Half of the subjects had a
>10-year duration since diagnosis with type 2 DM.
According to patient questionnaires, the most frequent
co-morbidities were hypertension (50.69 %) and dyslipid-
emia (37.5 %) (not shown in Table 1). Examination of
medical records revealed that antihypertensive drugs, sta-
tins, and antiplatelet agents were prescribed to 43.3 %,
42.3 %, and 41.2 % of all patients, respectively. Approxi-
mately 20 % of the patients were current smokers. The
mean HbA1C level was 60 ± 18.6 mmol/mol. The mean
LDL-C level was 2.57 ± 0.86 mmol/L.
Estimated cardiovascular risk of the subjects
In total, 42.9 % of the subjects with diabetes had a posi-
tive finding for atherosclerosis according to carotid US
(Table 1). Of the 622 patients assessed using the UKPDS
calculator, 43.6 % were positive for atherosclerosis ac-
cording to carotid US. The UKPDS risk calculator deter-
mined that 343 (55.2 %) patients were at low risk for
CVD, 213 (34.2 %) patients were at intermediate risk for
CVD, and 66 (10.6 %) patients were at high risk for
CVD. The FRS algorithm determined that 425 (65.6 %)
patients were at low risk for CVD, 195 (30.1 %) patients
were at intermediate risk for CVD, and 28 (4.3 %)
patients were at high risk for CVD (Table 1). The 10-
year risk of CVD was higher in the UKPDS high-risk
group compared to the FRS high-risk group (10.6 % vs.
4.3 %, p < 0.0001).
We also calculated the UKPDS and FRS cutoff points
for the prediction of positive CUS (IMT > 1 mm). The
UKPDS cutoff was 14.52 (sensitivity 66.38 %, specificity
61.99 %) and the FRS cutoff was 14 (sensitivity 72.75 %,
specificity 46.62 %).
There was a significant correlation between CV risk
score and carotid IMT. The correlation coefficient be-
tween UKPDS score and mean IMT was 0.295 (p < 0.001).
The correlation coefficient between FRS score and mean
IMT was 0.227 (p < 0.001).
We next investigated whether the UKPDSRE or FRS
calculator is a superior predictor of positive CUS. The
area under the UKPDSRE ROC curve was 0.677 (95 %
CI, 0.635, 0.719), while the area under the FRS ROC
curve was 0.629 (95 % CI, 0.584, 0.672); this difference
was significant (P = 0.001). Therefore, the UKPDSRE
calculator was better at predicting positive CUS than the
FRS algorithm.
Patient clinical characteristics according to positive
carotid ultrasound findings
Patients with positive carotid ultrasound findings were
significantly older (63.5 ± 9.0 vs. 57.9 ± 9.2 years), had a
longer duration of diabetes (9.0 ± 7.6 vs. 7.4 ± 6.7 years),
used more antihypertensive medication (50.0 vs. 38.2 %)
and antiplatelet agents (46.2 vs. 37.4 %), and had higher
log hs-CRP levels (−1.4 ± 1.7 vs. −1.0 ± 1.8 mg/L) com-
pared to subjects with negative carotid US findings
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(Table 1). Furthermore, the UKPDSRE and FRS scores
were higher in subjects with positive carotid IMT find-
ings. In addition, the percentages of high risk patients as
classified by the UKPDSRE and FRS systems were higher
for subjects with positive carotid IMT findings compared
to subjects with negative findings (18.8 vs. 4.3 % and 7.8
vs. 1.7 %, respectively) (Table 1).
Multiple logistic regression analysis was next per-
formed to investigate the associations between CV risk
factors and abnormal carotid US findings after adjusting
for age and sex. Carotid IMT was positively correlated
with LDL-C level. There was a trend towards a positive
association between ex- and current smokers and posi-
tive carotid IMT findings. No significant associations
were noted between positive CUS findings and BP, BMI,
DM duration, HbA1C, UKPDSRE score, or FRS score
(Table 2).
Prevalence of carotid atherosclerosis according to risk
stratification scores
According to the UKPDS risk engine, the prevalences
of positive carotid US findings were 31.5 % in the
low-risk group, 52.6 % in the intermediate-risk group,
and 77.3 % in the high-risk group. According to the
Table 1 Baseline clinical characteristics of patients with versus without subclinical atherosclerosis
Atherosclerosis Findings via Carotid IMT
Total (N = 797) Negative (N = 455) Positive (N = 342) *P-value
Age (years) 60.0 ± 9.5 57.9 ± 9.2 63.5 ± 9.0 <0.001
Sex (percent male) 395 (49.6) 227 (49.9) 175 (51.2) 0.721
BMI (kg/m2) 25.1 ± 3.1 25.3 ± 3.4 24.9 ± 3.0 0.067
Waist circumference (cm) 87.2 ± 8.2 87.6 ± 8.6 86.7 ± 7.6 0.164
Blood pressure (mmHg)
Systolic 125.3 ± 14.5 124.5 ± 14.7 126.5 ± 14.2 0.060
Diastolic 75.3 ± 10.1 75.7 ± 9.6 74.7 ± 10.6 0.170
DM duration (years) 8.1 ± 7.1 7.4 ± 6.7 9.0 ± 7.6 0.002
Medication use [N (%)]
Antihypertensive drug 345 (43.3) 174 (38.2) 171 (50.0) 0.001
Statin 337 (42.3) 195 (42.9) 142 (41.5) 0.705
Antiplatelet agent 328 (41.2) 170 (37.4) 158 (46.2) 0.012
Current smoker (%) 153 (19.2) 81 (17.9) 72 (21.1) 0.253
Glucose (mmol/L) 8.1 ± 2.8 8.0 ± 2.7 8.2 ± 3.0 0.591
HbA1C (mmol/mol) 60 ± 18.6 60 ± 17.5 61 ± 19.7 0.417
Log hs-CRP (mg/L) −1.2 ± 1.8 −1.4 ± 1.7 −1.0 ± 1.8 0.017
Total cholesterol (mmol/L) 4.4 ± 1.0 4.4 ± 1.0 4.5 ± 1.0 0.710
Triglycerides (mmol/L) 1.7 ± 1.1 1.7 ± 1.2 1.7 ± 1.0 0.884
LDL-C (mmol/L) 2.6 ± 0.9 2.5 ± 0.9 2.6 ± 0.8 0.284
HDL-C (mmol/L) 1.2 ± 0.4 1.3 ± 0.3 1.2 ± 0.4 0.594
UKPDS risk engine score 16.8 ± 12.1 13.3 ± 8.7 20.4 ± 13.6 <0.001
UKPDS risk engine (%) (N = 622)
High 66 (10.6) 15 (4.3) 51 (18.8)
Intermediate 213 (34.2) 101 (28.8) 112 (41.3) <0.001
Low 343 (55.2) 235 (67.0) 108 (39.9)
Framingham risk score 7.7 ± 6.4 6.2 ± 5.7 9.20 ± 7.1 <0.001
Framingham risk engine (%) (N = 648)
High 28 (4.3) 6 (1.6) 22 (7.8)
Intermediate 195 (30.1) 88 (24.0) 107 (38.1) <0.001
Low 425 (65.6) 273 (74.4) 152 (54.1)
IMT intima medial thickness, BMI body mass index, DM diabetes mellitus, CRP C-reactive protein, LDL-C low-density lipoprotein cholesterol, HDL high-density
lipoprotein cholesterol, UKPDS United Kingdom Prospective Diabetes Study
*P-value: comparison of clinical data between patients who were negative versus positive for carotid atherosclerosis according to carotid IMT
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FRS algorithm, the prevalences of abnormal carotid
US findings were 35.8 % in the low-risk group,
54.9 % in the intermediate-risk group, and 78.6 % in
the high-risk group (Fig. 1). Overall, about one-third
of the patients in both low-risk groups had a positive
finding according to carotid US. On the other hand,
only about 20 % of the patients in both high-risk
groups had a negative finding according to carotid US
(Fig. 1).
Factors contributing to the discrepancy between UKPDS
risk engine stratification and carotid US findings
In total, 39.9 % of subjects with a positive CUS finding
were classified as low-risk according to the UKPDSRE
calculator (Table 1). To identify the factors that were
associated with abnormal CUS findings in patients
assessed by the UKPDSRE calculator, we compared the
clinical parameters of patients with negative versus
positive CUS findings in each risk-stratified group. In
the low-risk group, patients with positive CUS findings
were significantly older and had a significantly lower
waist circumference, lower diastolic BP, a higher preva-
lence of hypertension and dyslipidemia, and a higher
prevalence of antihypertensive medication use com-
pared to subjects with negative CUS findings. In the
intermediate-risk group, positive CUS findings were
associated with increased age, female sex, and higher
hs-CRP levels compared to subjects with negative CUS
findings. In the high-risk group, no significant associa-
tions were observed between any parameter and posi-
tive CUS findings between the two groups (Additional
file 1: Table S1). This finding may be due to the rela-
tively small number of subjects in the high-risk group.
Changes in treatment patterns after CUS measurements
Changes in physician prescriptions were investigated at
6 months after the initial CUS measurements. Awareness
of high-risk CUS findings significantly altered physician
treatment patterns (p = 0.011) for managing major CV risk
factors. In addition, significant increases in the addition
and dosages of anti-hypertensive drugs (p = 0.013) and an-
tiplatelet agents (p = 0.003) were observed in patients with
positive CUS findings (Table 3).
The percentage of subjects who achieved the target
LDL-C goal (<2.59 mmol/L) was significantly higher
6 months after CUS examination in patients with negative
CUS findings and also in patients with positive CUS find-
ings (Table 3). Abnormal CUS findings affected physician
behavior regardless of patient risk level according to the
UKPDSRE calculator. A significant change in treatment
patterns for antihypertensive drug use (7.0 vs. 14.6 %) was
observed in patients with positive CUS findings who were
identified as low-risk according to the UKPDS calculator.
Table 2 Associations between carotid intima medial thickness
and cardiovascular disease risk factorsa
OR 95 % CI P-value
BMI 1.051 0.945, 1.169 0.835
Systolic blood pressure 1.010 0.994, 1.027 0.219
DM duration 0.997 0.963, 1.033 0.887
Ex & current smokers 1.771 0.907, 3.459 0.094
HbA1C 1.006 0.843, 1.201 0.946
Triglycerides 1.002 0.999, 1.005 0.142
LDL-C 1.018 1.003, 1.032 0.017
HDL-C 1.013 0.985, 1.042 0.360
UKPDS risk engine score 27.003 0.057, 999.999 0.294
Framingham risk score 0.971 0.900, 1.047 0.441
OR odds ratio, CI confidence interval, BMI body mass index, DM diabetes
mellitus, LDL-C low-density lipoprotein cholesterol, HDL high-density
lipoprotein cholesterol, UKPDS United Kingdom Prospective Diabetes Study
aValues adjusted for age and sex
Fig. 1 Prevalences of carotid atherosclerosis according to UKPDS engine score (a) and Framingham risk score (b). Open bar: negative findings
from carotid ultrasound. Black bar: positive findings from carotid ultrasound
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A significant change in treatment patterns for antiplatelet
agent use (0 vs. 22.0 %) was also observed in patients with
positive CUS findings who were identified as high-risk
according to the UKPDSRE calculator (Additional file 1:
Table S2).
Changes in patient behavior after education based on
carotid US results
Interviews were performed 6 months after patients were
informed of their carotid US results. Overall, patients
who were informed of their CUS results exhibited
significant changes in their health-related behaviors. For
example, the rates of smoking cessation and dietary
changes (p < 0.005 each) were both increased at the 6-
month follow-up visit. Moreover, the percentage of pa-
tients who had quit smoking had significantly increased
and the amount of soup intake had reduced significantly
at six months after the CUS examination (Fig. 2). This
finding suggests that the patients tried to reduce their
salt intake by decreasing their soup consumption.
Discussion
Our results suggest that CUS can identify CVD-
vulnerable patients out of the population of patients with
type 2 DM with low-risk or intermediate-risk stratification
scores. In addition, improved awareness of CVD risk
based on carotid IMT results can improve CV risk man-
agement by increasing the prevention efforts of both phy-
sicians and patients.
According to CUS, 271 (43.5 %) patients were at high
risk for CVD. In contrast, only 66 (10.6 %) and 28
(4.3 %) patients were at high risk for CVD according to
the UKPDSRE calculator and the FRS algorithm, re-
spectively. We also found that more high-risk patients
were identified using the UKPDSRE calculator com-
pared to the FRS algorithm (10.6 vs. 4.5 %, p < 0.0001).
This finding was not surprising, since the UKPDS risk
engine was developed especially for use with patients
with diabetes [5]. As such, this method has a higher
prognostic value for coronary heart disease in patients
newly diagnosed with type 2 diabetes [14]. Also, the
UKPDSRE calculator provided the highest odds ratios
for predicting carotid atherosclerosis in Korean patients
with type 2 diabetes compared to the FRS and the
SCORE methods [15]. However, the prevalences of
positive CUS findings were very similar in the low-risk
(31.5 % vs. 35.8 %), intermediate-risk (52.6 % vs.
54.9 %), and high-risk (77.3 % vs. 78.6 %) groups for
both the UKPDS risk engine and the FRS algorithm,
respectively (Fig. 1).
Table 3 Changes in treatment patterns after knowledge of subclinical carotid atherosclerosis results







Changed 96 (24.7) 107 (33.4) 0.011
Additional medications
Anti-hypertensive drugs 32 (8.3) 45 (18.1) 0.013
Lipid-lowering drugs 52 (13.4) 44 (13.8) 0.893
Antiplatelet agents 26 (6.7) 43 (13.4) 0.003
Achievement of treatment target goals
BP (<130/80 mmHg)
At baseline 210 (49.1) (N = 428) 142 (46.3) (N = 307) 0.452
After 6 months 199 (46.5) (N = 428) 139 (45.3) (N = 307) 0.744
Baseline vs. 6 months P = 0.389 P = 0.785
LDL-C (<2.59 mmol/L)
At baseline 112 (57.7) (N = 194) 80 (55.6) (N = 144) 0.690
After 6 months 130 (67.0) (N = 194) 105 (72.9) (N = 144) 0.243
Baseline vs. 6 months P = 0.022 P < 0.001
Calculated LDLa (<2.59 mmol/L)
At baseline 125 (56.8) (N = 220) 96 (56.8) (N = 169) 0.998
After 6 months 157 (71.4) (N = 220) 126 (74.6) (N = 169) 0.483
Baseline vs. 6 months P = 0.022 P < 0.001
BP blood pressure, LDL-C low-density lipoprotein cholesterol
aCalculated LDL = total cholesterol – (triglyceride/5) – HDL
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The FRS and UKPDSRE approaches, both of which
include traditional CV risk factors, have been validated for
predicting CV risk in Asian populations [15–17]. Although
the results of these approaches are generally correlated
with subclinical atherosclerosis, the majority of CVD
events occur in patients with low or intermediate risk of
CVD [4]. To our surprise, one-third of the low-risk pa-
tients according to both the UKPDSRE and FRS classifica-
tions had a positive CUS finding. Of the patients classified
as low-risk based on their UKPDSRE score, 39.9 % had a
positive CUS finding. One previous study found that
32.8 % of all women and 40.5 % of all men with low
(<10 %) to intermediate (10–20 %) risk of CVD according
to the FRS algorithm had subclinical atherosclerosis [6].
Analysis of factors related to atherosclerosis in the low-risk
group indicated that positive CUS findings were signifi-
cantly associated with older age, higher prevalences of
hypertension and dyslipidemia, and a higher prevalence of
antihypertensive medication history.
Carotid IMT and the presence of carotid plaque are
important markers of subclinical atherosclerosis that can
be used to predict cardiovascular morbidity. Many
epidemiology studies, such as the Atherosclerosis Risk in
Communities (ARIC) study [18] and the Insulin Resist-
ance Atherosclerosis Study (IRAS) [19], have demonstrated
that age, male sex, smoking, hypertension, dyslipidemia,
and postmenopausal status are independent correlates of
carotid atherosclerosis. In particular, Chin et al. [20] showed
that LDL-C levels in males and HDL-C levels in females
were risk factors for IMT progression among patients
newly diagnosed with type 2 diabetes. We found that old
age, diabetes duration, percentage of antihypertensive medi-
cation use, antiplatelet agent use, and log hs-CRP level were
significantly higher in patients with positive CUS findings.
After adjustment for age and sex, LDL-C was an independ-
ent correlate of subclinical carotid atherosclerosis. These
data suggest that LDL-C should be managed to protect or
delay the progression of atherosclerosis. Therefore, compre-
hensive management of CV risk factors and patient adher-
ence to the treatment plan may prevent or delay the
progression of atherosclerosis.
We also assessed how patient lifestyle and physician
prescriptions changed after receiving the CUS results, as
well as how knowing these results affected the achieve-
ment of target lipid and BP levels after 6 months. Among
the patients with positive CUS findings, significant in-
creases in the use or dosage of anti-hypertensive drugs
and antiplatelet agents were observed compared to those
in patients with negative CUS findings. We speculate that
learning that a patient had subclinical atherosclerosis of
the carotid artery may have encouraged physicians to
more intensively manage patient risk factors for athero-
sclerosis. In addition, this intervention was associated with
a significant improvement in the achievement of target
LDL-C levels, even though a change in medication
prescriptions related to hypercholesterolemia was not ob-
served. This finding implies that medication compliance
for lipid-lowering drugs might increase after patients
receive their CUS findings, regardless of whether these
findings are negative or positive. Hong et al. [21] reported
that among asymptomatic patients with hypertension, ath-
erosclerosis detection by CUS significantly increased the
proportion of patients who achieved their target LDL-C
levels compared to patients who received a negative CUS
finding. However, we found that patient knowledge of
CUS findings improved outcomes, regardless of whether
the results were positive or negative. As such, we propose
that CUS is a beneficial tool for increasing adherence to
lipid-lowering drug regimens as part of CV risk manage-
ment in patients with type 2 diabetes.
Patient behaviors also changed significantly after the pa-
tients received their CUS results. Specifically, patients
who underwent CUS examination subsequently reduced
smoking and salt intake (for the latter, by reducing soup
consumption). We infer that since consumption of Korean
soup or stew has been shown to be associated with high
salt intake [22], patients made an effort to reduce their salt
intake by decreasing their soup consumption. Thus, our
data indicate that knowledge of carotid US results and
subsequent explanation of the relevant CVD risks is a
useful approach for enabling patients to achieve the
recommended lifestyle modifications. Furthermore, CUS
is a very helpful tool that enables patients to better under-
stand their atherosclerosis status, particularly when CUS
Fig. 2 Changes in behavior (a) and diet (b) in patients after education
based on carotid US results. [※: p < 0.05 between behavior before
(open bar) and after (black bar) awareness of positive findings from
carotid ultrasound]
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imaging results are employed. Our results thus indicate
that explanation of CUS results assists patients with
diabetes and their physicians to achieve patient thera-
peutic targets through behavior changes and medication
plan alterations.
This study did have some limitations. First, the study
period was only 6 months, which is a relatively short period
of time for full evaluation of CVD event outcomes. Second,
although our results indicated that awareness of CUS re-
sults may positively influence physician management of CV
risk factors and patient behavior, correlation does not imply
causality. Third, we did not evaluate the quality or area of
the carotid plaques found by CUS. Several studies have
shown that the quality of plaque and the plaque area are
more strongly predictive of CV events than IMT [23, 24].
Fourth, we defined a positive CUS finding as an IMT ≥
1 mm or the presence of plaque. We chose these criteria
based on several large clinical studies (e.g. the ARIC study
and studies performed in Finland) that compared the
hazard ratios between CIMT ≥ 1 mm and < l mm [25–27].
Specifically, the ARIC study showed that the hazard ratio
comparing extreme mean CIMT (≥1 mm) to not extreme
CIMT (<1 mm) was 5.07 for women and 1.85 for men.
Above 1 mm, the CV event rates were elevated [26]. How-
ever, this cutoff point was derived from a non-Asian popu-
lation. To more accurately predict CV risk in future
studies, a more comprehensive investigation of the optimal
CIMT cutoff point to predict CV risk in an Asian popula-
tion would be beneficial. Finally, all subjects in the present
study were Asian, and thus our findings may not be applic-
able to other populations.
Conclusions
Our data indicate that CUS screening is an effective
method for identifying patients with subclinical athero-
sclerosis, even among patients considered to be low-risk
according to the UKPDRES or FRS approach. In addition,
educating patients with type 2 DM about their athero-
sclerosis risk as determined by their CUS results may
result in improved management of CV risk factors.
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